Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
BioVaxys Technology ( (TSE:BIOV) ) just unveiled an announcement.
BioVaxys Technology Corp. has announced an extension to the closing date of its non-brokered private placement offering, allowing more time for investors to participate. The company plans to use the proceeds for working capital, which could impact its operational capabilities and market positioning.
More about BioVaxys Technology
BioVaxys Technology Corp., based in British Columbia, Canada, is a clinical-stage biopharmaceutical company specializing in innovative immunotherapies. Their focus is on using the DPX™ and HapTenix© platforms to address cancers, infectious diseases, antigen desensitization, and other immunological areas.
YTD Price Performance: -20.0%
Average Trading Volume: 564,663
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.82M
For an in-depth examination of BIOV stock, go to TipRanks’ Stock Analysis page.
